A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Treatment Resistant Major Depressive Disorder
Interventions
DRUG

AXS-05

AXS-05 taken daily for 6 weeks.

DRUG

Bupropion

Buproprion taken daily for 6 weeks.

Trial Locations (74)

11432

Jamaica

20016

Washington D.C.

30328

Atlanta

32256

Jacksonville

38119

Memphis

Unknown

Phoenix

Little Rock

Anaheim

Beverly Hills

Garden Grove

Oakland

Oceanside

Panorama City

Redlands

Riverside

San Diego

San Francisco

Sherman Oaks

Temecula

Upland

Colorado Springs

Cromwell

Coral Springs

Fort Lauderdale

Fort Myers

Gainesville

Lakeland

North Miami

Orlando

Pensacola

St. Petersburg

Boise

Skokie

Shreveport

Baltimore

Saint Charles

St Louis

Lincoln

Las Vegas

Nashua

Berlin

Cherry Hill

Marlton

Princeton

Toms River

Albuquerque

Brooklyn

New York

Rochester

Staten Island

Charlotte

Canton

Dayton

Middleburg Heights

Oklahoma City

Portland

Salem

Allentown

Media

Philadelphia

Lincoln

Charleston

Austin

Dallas

Houston

San Antonio

Wichita Falls

Orem

Charlottesville

Herndon

Bellevue

Seattle

Spokane

Waukesha

Sponsors
All Listed Sponsors
lead

Axsome Therapeutics, Inc.

INDUSTRY